Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis

PURPOSE: Anti-programmed cell death receptor-1 (PD-1) antibodies have demonstrated antitumor activity in many cancer entities. Hepatic adverse events (AEs) are one of its major side effects, but the overall risks have not been systematically evaluated. Thus, we conducted this meta-analysis to invest...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xi, Ran, Yuge, Wang, Kunjie, Zhu, Yuanxue, Li, Jinghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047728/
https://www.ncbi.nlm.nih.gov/pubmed/27729774
http://dx.doi.org/10.2147/DDDT.S115493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047728/
https://www.ncbi.nlm.nih.gov/pubmed/27729774
http://dx.doi.org/10.2147/DDDT.S115493

Ejemplares similares